IMPORTANT: THIS DOCUMENT IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION. IF IN DOUBT, PLEASE SEEK PROFESSIONAL ADVICE.

Each of The Stock Exchange of Hong Kong Limited, Hong Kong Exchanges and Clearing Limited ("**HKEx**"), Hong Kong Securities Clearing Company Limited and the Securities and Futures Commission (the "**SFC**") takes no responsibility for the contents of this Announcement, makes no representation as to its accuracy or completeness and expressly disclaims any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this Announcement.

The Manager accepts full responsibility for the accuracy of the information contained in this Announcement as at the date of publication, and confirms, having made all reasonable enquiries, that to the best of its knowledge and belief, as at the date of publication, opinions expressed in this Announcement have been arrived at after due and careful consideration.

SFC authorisation is not a recommendation or an endorsement of a scheme nor does it guarantee the commercial merits of a scheme or its performance. It does not mean the scheme is suitable for all investors nor is it an endorsement of its suitability for any particular investor or class of investors.

ChinaAMC Global ETF Series (the "Trust")

(a Hong Kong umbrella unit trust authorized under Section 104 of the Securities and Futures Ordinance (Cap. 571) of Hong Kong)

ChinaAMC Hang Seng Biotech ETF

HKD Counter Stock Code: 03069
RMB Counter Stock Code: 83069
USD Counter Stock Code: 09069

(the "Sub-Fund")

Announcement
Revision to index methodology

Unless otherwise defined in this Announcement, capitalised terms used in this Announcement shall have the same meaning as defined in the prospectus of the Trust and the Sub-Fund (the "**Prospectus**").

China Asset Management (Hong Kong) Limited (the "**Manager**"), the manager of the Sub-Fund, hereby announces that Hang Seng Indexes Company Limited (the "**Index Provider**"), being the index provider of Hang Seng Biotech Index (the "**Index**"), which is the underlying index of the Sub-Fund, has introduced changes to the index methodology of the Index (the "**Revised Methodology**"). The Revised Methodology is applied in the index review for the period ending 30 June 2026, and the corresponding changes are effective on 14 September 2026 (the "**Effective Date**").

1. Changes to the Hang Seng Industry Classification System

As a result of changes to the Hang Seng Industry Classification System, the Revised Methodology incorporates the addition of a new subsector named "Pharma & Biotech Contract Services" under the Hang Seng Industry Classification System, which includes companies providing contract research, development, and manufacturing services to pharmaceutical and biotechnology firms, covering drug discovery, development, and manufacturing stages.

In addition, the subsector named "Medical Devices & Supplies" under the Hang Seng Industry Classification System is updated to include companies developing, manufacturing, and distributing medical equipment, devices, and consumables, including smart devices with digital or artificial intelligence features such as medical robots and products certified for medical use or primarily marketed for medical diagnosis, treatment or monitoring.

2. Impact on the Sub-Fund

The Manager confirms that (i) the above changes will not amount to material changes to the Sub-Fund; (ii) there will be no material change or increase in the overall risk profile of the Sub-Fund as a result of the changes; and (iii) there will be no material adverse impact on Unitholders' rights or interests (including changes that may limit Unitholders' ability in exercising their rights).

3. General

The updated Prospectus and product key fact statements of the Sub-Fund are available on the Effective Date to reflect the relevant changes and other miscellaneous updates, and are uploaded on the Manager's website at www.chinaamc.com.hk (this website has not been reviewed by the SFC) and (in respect of offering documents of Listed Class of Units of the Sub-Fund) the HKEx's website at www.hkex.com.hk.

Investors who have any enquiries regarding the above may contact the Manager at 37/F, Bank of China Tower, 1 Garden Road, Central, Hong Kong or our enquiry hotline at (852) 3406 8686 during office hours.

China Asset Management (Hong Kong) Limited
as Manager of the Trust and the Sub-Fund
14 September 2026